IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v18y2020i1p113-d468644.html
   My bibliography  Save this article

Antibiotics (Macrolides and Lincosamides) Consumption Trends and Patterns in China’s Healthcare Institutes. Based on a 3 Year Procurement Records, 2015–2017

Author

Listed:
  • Wenchen Liu

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Ali Hassan Gillani

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Sen Xu

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Chen Chen

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Jie Chang

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Caijun Yang

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Wenjing Ji

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Minghuan Jiang

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Mingyue Zhao

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

  • Yu Fang

    (Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an 710061, China
    Center for Drug Safety and Policy Research, Xi’an Jiaotong University, Xi’an 710061, China
    Shaanxi Center for Health Reform and Development Research, Xi’an Jiaotong University, Xi’an 710061, China
    Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, China’s Western Technological Innovation Harbor, Xi’an 710049, China)

Abstract

In this study, we investigated the trends and patterns of antibiotic consumption (macrolides and lincosamides) in China’s healthcare institutions from 2015 to 2017. The China Drug Supply Information Platform (CDSIP) was officially launched in 2015. We collected records from this national centralized bidding procurement system between 2015 and 2017. The use of J01F antibiotics (macrolides or lincosamides) was calculated in a defined daily dose per 1000 inhabitants per day (DID).Purchase data from 70,366 national medical facilities included in the CDSIP were collected. The procurement data of 66,007 medical facilities have not changed over 3 years. There is a slight decline in the consumption of J01F antibiotics, which decreased from 3.03 DID in 2015 to 2.91 DID in 2017. Azithromycin (20.6%) was the most commonly used antibiotic in 2017 among all classes, followed by clindamycin (17.9%) and erythromycin (13.7%). Parenteral antibiotics accounted for 32.0% of total antibiotic consumption and 59.6% of total antibiotics expenditure in 2017. The overall consumption of most antibiotics decreased slightly over the 3-yearstudy period. This may be owing to China’s health-related policies in the past few years. A gap still exists in antibiotic use between regions and dosage forms. Further studies are needed to optimize antibiotic prescribing and reduce antibiotic resistance.

Suggested Citation

  • Wenchen Liu & Ali Hassan Gillani & Sen Xu & Chen Chen & Jie Chang & Caijun Yang & Wenjing Ji & Minghuan Jiang & Mingyue Zhao & Yu Fang, 2020. "Antibiotics (Macrolides and Lincosamides) Consumption Trends and Patterns in China’s Healthcare Institutes. Based on a 3 Year Procurement Records, 2015–2017," IJERPH, MDPI, vol. 18(1), pages 1-9, December.
    • Handle: RePEc:gam:jijerp:v:18:y:2020:i:1:p:113-:d:468644
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/18/1/113/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/18/1/113/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Currie, Janet & Lin, Wanchuan & Zhang, Wei, 2011. "Patient knowledge and antibiotic abuse: Evidence from an audit study in China," Journal of Health Economics, Elsevier, vol. 30(5), pages 933-949.
    2. Xinping Zhang & Youwen Cui & Chaojie Liu & Keyuan Zuo & Yuqing Tang, 2019. "Antibiotic Sales in Primary Care in Hubei Province, China: An Analysis of 2012–2017 Procurement Records," IJERPH, MDPI, vol. 16(18), pages 1-13, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mujcic, Redzo & Frijters, Paul, 2013. "Still Not Allowed on the Bus: It Matters If You're Black or White!," IZA Discussion Papers 7300, Institute of Labor Economics (IZA).
    2. Wang, Jing & Gong, Yanhong & Wu, Jianxiong & Jiang, Nan & Chen, Zhenyuan & Yin, Xiaoxv, 2021. "Antibiotic dispensing patterns and patient interventions for upper respiratory tract infections by hospitals and retail pharmacies: A cross-sectional study based on standardized patients," Social Science & Medicine, Elsevier, vol. 272(C).
    3. Chen, Chun & Dong, Weizhen & Shen, Jay J. & Cochran, Christopher & Wang, Ying & Hao, Mo, 2014. "Is the prescribing behavior of Chinese physicians driven by financial incentives?," Social Science & Medicine, Elsevier, vol. 120(C), pages 40-48.
    4. Lu, Fangwen, 2014. "Insurance coverage and agency problems in doctor prescriptions: Evidence from a field experiment in China," Journal of Development Economics, Elsevier, vol. 106(C), pages 156-167.
    5. Maria Vittoria Levati & Ivan Soraperra & Saba Yifredew, 2023. "How to Curb Over-The-Counter Sales of Antibiotics? Evidence from a Field Experiment in Ethiopia," Working Papers 10/2023, University of Verona, Department of Economics.
    6. Chenxi Liu & Chaojie Liu & Dan Wang & Xinping Zhang, 2019. "Knowledge, Attitudes and Intentions to Prescribe Antibiotics: A Structural Equation Modeling Study of Primary Care Institutions in Hubei, China," IJERPH, MDPI, vol. 16(13), pages 1-16, July.
    7. Felix C.H. Gottschalk, 2019. "Why prevent when it does not pay? Prevention when health services are credence goods," Health Economics, John Wiley & Sons, Ltd., vol. 28(5), pages 693-709, May.
    8. Toshiaki Iizuka & Hitoshi Shigeoka, 2018. "Free for Children? Patient Cost-sharing and Healthcare Utilization," NBER Working Papers 25306, National Bureau of Economic Research, Inc.
    9. Deiana, Claudio & Giua, Ludovica & Nistico, Roberto, 2019. "The Economics behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US," IZA Discussion Papers 12872, Institute of Labor Economics (IZA).
    10. Currie, Janet & Lin, Wanchuan & Meng, Juanjuan, 2013. "Social networks and externalities from gift exchange: Evidence from a field experiment," Journal of Public Economics, Elsevier, vol. 107(C), pages 19-30.
    11. Wu, Bingxiao, 2019. "Physician agency in China: Evidence from a drug-percentage incentive scheme," Journal of Development Economics, Elsevier, vol. 140(C), pages 72-89.
    12. Anja Sautmann & Samuel Brown & Mark Dean, 2016. "Subsidies, Information, and the Timing of Childrenís Health Care in Mali," Working Papers 2016-2, Brown University, Department of Economics.
    13. repec:iab:iabjlr:v:55:i::p:art.6 is not listed on IDEAS
    14. Zamora, Paula & Mantilla, César & Blanco, Mariana, 2021. "Price discrimination in informal labor markets in Bogotá: an audit experiment during the 2018 FIFA World Cup," Journal for Labour Market Research, Institut für Arbeitsmarkt- und Berufsforschung (IAB), Nürnberg [Institute for Employment Research, Nuremberg, Germany], vol. 55, pages 1-6.
    15. Currie, Janet & Lin, Wanchuan & Meng, Juanjuan, 2014. "Addressing antibiotic abuse in China: An experimental audit study," Journal of Development Economics, Elsevier, vol. 110(C), pages 39-51.
    16. Andia, Tatiana & Mantilla, César & Morales, Álvaro & Ortiz, Santiago & Rodríguez-Lesmes, Paul, 2022. "Does price-cap regulation work for increasing access to contraceptives? Aggregate- and pharmacy-level evidence from Colombia," Social Science & Medicine, Elsevier, vol. 311(C).
    17. Bingxiao Wu, 2014. "Mismeasurement in Pay-for-Performance: Evidence from an Intervention to Reduce Health Care Spending in China," Departmental Working Papers 201409, Rutgers University, Department of Economics.
    18. Felix Gottschalk, 2021. "Regulating Markets with Advice: An Experimental Study," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 83(1), pages 1-31, February.
    19. Jiwei Qian & Alex Jingwei He, 2018. "The Bonus Scheme, Motivation Crowding-out and Quality of the Doctor-Patient Encounters in Chinese Public Hospitals," Public Organization Review, Springer, vol. 18(2), pages 143-158, June.
    20. Ding, Hui & Chen, Yiwei & Yu, Min & Zhong, Jieming & Hu, Ruying & Chen, Xiangyu & Wang, Chunmei & Xie, Kaixu & Eggleston, Karen, 2021. "The Effects of Chronic Disease Management in Primary Health Care: Evidence from Rural China," Journal of Health Economics, Elsevier, vol. 80(C).
    21. Daniel Bennett & Che-Lun Hung & Tsai-Ling Lauderdale, 2015. "Health Care Competition and Antibiotic Use in Taiwan," Journal of Industrial Economics, Wiley Blackwell, vol. 63(2), pages 371-393, June.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2020:i:1:p:113-:d:468644. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.